Updated:
Inhibitor Therapeutics
Focused on developing innovative therapies for patients with cancer and non-cancerous proliferation disorders. | INHIBITOR Therapeutics, Inc.
Inhibitor Therapeutics
Focused on developing innovative therapies for patients with cancer and non-cancerous proliferation disorders. | INHIBITOR Therapeutics, Inc. is a publicly traded pharmaceutical company (OTCQB:INTI) focused on developing and commercializing innovative therapies for patients with cancer and non-cancerous proliferation disorders.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
Is Inhibitor Therapeutics a family office or asset manager?
No. Inhibitor Therapeutics is a publicly traded company (OTC: INHI) focused on drug development. It has not disclosed any investment management function, AUM, or relationship with a family office.
What is Inhibitor Therapeutics' lead drug program?
The company's primary program involves repurposing bortezomib, a proteasome inhibitor, for relapsed or refractory multiple myeloma. It has not reported Phase III trial data or regulatory submissions.
Who manages investment decisions at Inhibitor Therapeutics?
The company has not identified a CEO, CIO, or investment team in public filings. Its executive management and board composition are not disclosed in a way that clarifies investment authority.
Does Inhibitor Therapeutics have any institutional investors?
The firm has not publicly named any institutional or accredited investors. Its stock trades on the OTC market, which does not require disclosure of major holders.
What is the wealth origin or capital source for Inhibitor Therapeutics?
No wealth origin or capital source has been disclosed. The firm appears to rely on public equity financing, but no specifics on funding rounds or backers are available.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: